AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Original) A method for rescuing damaged nerve cells in a patient, comprising:

administering to a patient having damaged nerve cells an amount of a deprenyl compound such that rescuing of damaged nerve cells occurs in the patient;

with the proviso that the deprenyl compound is not selected from the group consisting of deprenyl, pargyline, AGN-1133, or AGN1135.

2. (Original) The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R_2 is hydrogen or alkyl;

R_3 is a single bond, alkylene, or $-(CH_2)_n-X-(CH_2)_m$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0,1, or 2;

R_4 is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylene; and

R_6 is C_3-C_6 cycloalkyl or

$-C\equiv CH$; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 2, wherein R_1 is a group that can be removed *in vivo*.

4. (Original) The method of claim 2, wherein R_1 is hydrogen.

5. (Original) The method of claim 2, wherein R_1 is alkyl.

6. (Original) The method of claim 5, wherein R_1 is methyl.

7. (Original) The method of claim 2, wherein R_2 is methyl.

8. (Original) The method of claim 2, wherein R_3 is methylene.

9. (Original) The method of claim 2, wherein R_4 is aryl.

10. (Original) The method of claim 2, wherein R_4 is phenyl.

11. (Original) The method of claim 2, wherein R_5 is methylene.

12. (Original) The method of claim 2, wherein R_6 is

$$—C\equiv CH$$

13. (Original) The method of claim 2, wherein the deprenyl compound has the structure



wherein R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl.

14. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylene;

and pharmaceutically acceptable salts thereof.

16. (Currently Amended) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

A is a substituent independently selected for each ~~occurence~~ occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxyl, cyano, nitro, amino, carboxyl, -CF_3, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17. (Original) The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.

18. (Cancelled)